EValuation of Erlotinib as a Neoadjuvant Therapy in Stage III Non-small Cell Lung Cancer Patients With EGFR Mutations (EVENT Trial)

Trial Profile

EValuation of Erlotinib as a Neoadjuvant Therapy in Stage III Non-small Cell Lung Cancer Patients With EGFR Mutations (EVENT Trial)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms EVENT
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Jan 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2017.
    • 28 Jan 2014 According ClinicalTrials.gov record, planned end date changed from 1 Jul 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top